Log In
BCIQ
Print this Print this
 

DE-105

  Manage Alerts
Collapse Summary General Information
Company Santen Pharmaceutical Co. Ltd.
DescriptionOphthalmic solution of neurotrophic factor peptide
Molecular Target
Mechanism of Action 
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase II
Standard IndicationCorneal wound
Indication DetailsTreat persistent corneal epithelial defects
Regulatory Designation
PartnerSucampo Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$273.9M

$273.9M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/07/2015

$273.9M

$273.9M

0

04/27/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today